Insider Trading November 21, 2026 08:16 AM

Vivos Inc President Brad Weeks Purchases $5,790 in Company Stock

The buy comes as shares trade at $0.04, down 9% in the past week and 42% year-to-date.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
RDGL

Brad Allan Weeks, President of VIVOS INC (RDGL), acquired 150,000 shares of the company's common stock on November 20, 2026, for a total of $5,790 at $0.0386 per share. Following the purchase, Weeks directly holds 1,697,204 shares. The stock trades at $0.04, down 9% over the past week and 42% year-to-date. Vivos Inc, with a market cap of $20.33 million, has struggled with profitability and weak gross profit margins of 6.83% over the last twelve months. An analysis suggests the stock is currently overvalued relative to its Fair Value estimate. Separately, Vivos Inc recently completed a $1 million equity offering, selling 12,500,000 shares at a par value of $0.001 per share under its Regulation A+ offering, with proceeds intended for general working capital purposes. The transaction, which included the issuance of new warrants, was disclosed in a press release filed with the Securities and Exchange Commission.

Vivos Inc President Brad Weeks Purchases $5,790 in Company Stock
RDGL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Brad Allan Weeks, President of VIVOS INC, purchased 150,000 shares for $5,790 at $0.0386 per share, increasing his direct holdings to 1,697,204 shares.
  • The stock trades at $0.04, down 9% over the past week and 42% year-to-date, with a market cap of $20.33 million and weak gross profit margins of 6.83%.
  • Vivos Inc completed a $1 million equity offering under Regulation A+, selling 12,500,000 shares at $0.001 par value, with proceeds for general working capital.

Brad Allan Weeks, the President of VIVOS INC (RDGL), has acquired 150,000 shares of the company's common stock, according to a recent filing. The transaction, executed on November 20, 2026, was valued at $5,790, with each share purchased at a price of $0.0386. The purchase occurred as the stock was trading at $0.04, reflecting a decline of 9% over the past week and a 42% drop year-to-date, based on data from InvestingPro.

With this acquisition, Mr. Weeks now directly holds 1,697,204 shares of VIVOS INC common stock. The company, which carries a market capitalization of $20.33 million, has faced challenges in achieving profitability and reported weak gross profit margins of just 6.83% over the last twelve months. An analysis by InvestingPro indicates that the stock is currently overvalued relative to its Fair Value estimate. Investors looking for deeper insights can access 6 additional InvestingPro Tips, along with comprehensive financial health scores and advanced metrics.

In separate recent developments, Vivos Inc announced the completion of a $1 million equity offering. The company sold 12,500,000 shares of common stock at a par value of $0.001 per share under its Regulation A+ offering. This transaction generated gross proceeds of $1,000,000, which Vivos Inc plans to allocate for general working capital purposes. The development was disclosed in a press release statement filed with the Securities and Exchange Commission. The completion of these equity transactions represents a significant financial move for the company. These recent developments highlight Vivos Inc's efforts to strengthen its financial position. The issuance of new warrants was also part of this transaction.

The insider purchase by the company's president offers a signal of internal confidence, though the broader context of the stock's performance and the company's financial metrics presents a mixed picture. The equity offering, while providing necessary capital, also results in dilution for existing shareholders. The company's ability to improve its gross margins and achieve profitability will be key factors to watch.

Risks

  • The company has struggled with profitability and weak gross profit margins, which may continue to pressure the stock.
  • The stock is considered overvalued relative to its Fair Value estimate, suggesting potential downside.
  • The equity offering may dilute existing shareholders and the company's ability to effectively deploy the proceeds is uncertain.

More from Insider Trading

Bank of America Reports Matching Buy and Sell of Nuveen Minnesota Fund Shares Nov 21, 2026 Medifast Director Parsa Kiai Discloses $1.13 Million Stock Purchase Nov 21, 2026 York Water Director Brossman Adds 31.971 Shares in Small Open-Market Purchase Nov 21, 2026 Solaris Energy President Ramachandran Buys $159,750 in Stock as Shares Retreat Nov 21, 2026 Legend Biotech CEO Ingrid Zhang Buys $163,200 in Shares Near 52-Week Low Nov 21, 2026